Starting MOQ
Starting MOQ is subject to formula, packaging and market documentation; request a project-specific quotation.
Freeze-dried and lyophilized skincare
Freeze-Dried Powder OEM & Lyophilized Skincare Manufacturing
Evaluate the powder format, activator concept, packaging system, and reconstitution steps as one buyer brief. The route is then scoped around the finished product and its intended market rather than a generic product claim.
Dosage form and reconstitution planning
Select a candidate format before you select a story.
The following are candidate routes subject to formula and packaging feasibility. Reconstitution is a development and user-experience decision, not a generic performance guarantee.
Scroll horizontally to compare all format and reconstitution columns.
| Buyer requirement | Candidate dosage form | Reconstitution decision to confirm | Commercial or technical limitation |
|---|---|---|---|
| Single-use application and simple consumer instructions | One powder unit plus one measured activator unit. | Powder fill target, activator volume, total reconstituted content, mixing instruction, and intended use quantity. | Confirm formula-pack compatibility and reconstitution performance before approval. |
| Multi-application routine in one pack | Powder vial with separate activator and dispensing component. | Intended number of uses, dose per use, total content, dispensing method, and post-reconstitution instructions. | Any in-use direction, preservation approach, or stability period must be established for the finished formula and pack. |
| Gift, travel, or treatment-style kit | Multiple unit-dose powder and activator pairs. | Number of units, unit content, kit configuration, user sequence, and outer-pack artwork. | Kit components, sourcing, assembly, and artwork can affect MOQ, cost, and readiness. |
| Professional or controlled-use concept | Project-specific multi-unit system. | User, setting, dose protocol, instructions, and market documentation needs. | Do not imply clinical, sterile, or professional-use suitability without project-specific evidence and market review. |
Development route
Move from concept to a project-ready system.
The route keeps the formula, activator, pack, instructions, documentation, and commercial inputs together. It is designed to surface decisions early rather than making assumptions about a finished product.
Build a development brief- 01
Qualify the brief
Confirm the target buyer or user, destination market, product role, claims boundary, order estimate, and commercial objective.
- 02
Choose dosage and reconstitution route
Align the dry format, activator concept, unit size, pack architecture, and intended user steps.
- 03
Develop and review prototypes
Assess appearance, reconstitution, sensory use, package compatibility, and the agreed acceptance criteria.
- 04
Define packaging and artwork inputs
Confirm components, pack configuration, label inputs, outer packaging, and artwork readiness.
- 05
Plan documentation and claim support
Identify market-specific documentation, testing, and substantiation questions before production planning.
- 06
Pass the production-readiness gate
Proceed only after formula approval, packaging confirmation, artwork sign-off, required market documentation, component availability, and agreed payment conditions are complete.
Current operating facts
Current operating facts for a freeze-dried project
Effective 2026-10-23 · Policy v2026.10.23.1
Quote response SLA
Within 1 business day after we receive a complete project inquiry.
Laboratory sample development
Target: 5–7 business days after the approved development brief.
Sample dispatch
Scheduled after sample approval; shipping transit is separate and confirmed with the destination.
Packaging confirmation
Project-specific after component sourcing, pack-compatibility review and artwork sign-off.
Bulk production
Target: 25–35 working days after the production-readiness gate is complete.
Production-readiness gate: Production timing starts only after formula approval, packaging confirmation, artwork sign-off, required market documentation, component availability and agreed payment conditions are complete.
Prepare your RFQ
Bring the details that make a project brief easier to scope.
Share what is available. The checklist gives the development and commercial teams a practical starting point; it does not replace project-specific confirmation.
- 01Company or brand, buyer role, and main contact.
- 02Destination market or markets and planned sales channel.
- 03Target consumer, product role, and desired claim territory.
- 04Preferred route: single unit, multi-use vial, kit, or a format to be assessed.
- 05Powder and activator concept, intended net content, dose or use assumptions, and desired user steps.
- 06Ingredient direction, exclusions, fragrance or colour preferences, and benchmark samples where available.
- 07Packaging preference, component count, outer-pack requirements, and artwork status.
- 08Documentation, label, claim-substantiation, and market-review needs.
- 09Estimated launch quantity, budget context, destination, shipping, and commercial requirements.
- 10Sample acceptance criteria and the buyer decision-maker or approval path.
Project boundaries
Confirm the conditions that shape a workable launch plan.
Clear boundaries protect the project brief. They help buyers distinguish a product direction from a confirmed formula, quote, market pathway, or production plan.
- Formula suitability: the ingredient system, powder structure, target dose, and reconstitution behavior need assessment together.
- Activator design: the liquid composition, volume, dispensing method, and instructions are separate decisions from the dry phase.
- Packaging: vial or unit selection, closures, droppers, component availability, and compatibility review may change the viable route.
- Claims and market: allowable communication and required documents depend on the intended market and finished-product evidence.
- Commercial conditions: starting MOQ is project-specific; formula, pack, artwork, documentation, component supply, and payment conditions affect readiness.
- Evidence boundary: do not assume potency retention, preservation status, shelf life, post-reconstitution use period, compatibility, or regulatory acceptance without project-specific evidence.
Related buyer reading
Use existing research to make the first brief more specific.
These resources support due diligence and concept planning. Finished-product feasibility, claims, documentation, and commercial terms remain subject to the project review.
Buyer FAQs
Questions procurement teams ask before they brief a project.
What is a freeze-dried powder skincare project?
It is a project that evaluates a dry powder formula and a separately defined reconstitution liquid or use procedure. Whether a proposed formula and pack are suitable is confirmed through the project development and packaging-review process.
Who is this OEM route for?
This route is for brands, retailers, clinics, and distributors that need a B2B manufacturer to assess a freeze-dried or lyophilized skincare concept, including dosage form, reconstitution, packaging, documentation planning, and quotation.
What must be confirmed before production planning begins?
Formula approval, packaging confirmation, artwork sign-off, required market documentation, component availability, and agreed payment conditions must be complete before production timing begins.
How are MOQ and project timing confirmed?
Starting MOQ is subject to formula, packaging, and market documentation. A project-specific quotation follows a complete inquiry. The current policy sets a bulk-production target of 25–35 working days only after the production-readiness conditions are complete.
Next step